Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 18 to 45

Using metformin to enhance antidepressant treatment in obese patients with depression

Official title: Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients

Run by Fazaia Ruth Pfau Medical College · NCT06707012 · Data updated 2026-11-12

This study is testing if adding metformin to the usual antidepressant treatment can help obese patients with depression feel better.

More Depression trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 45 Years
SexAll
Enrollment140 (estimated)
SponsorFazaia Ruth Pfau Medical College
Academic / other
Locations2 sites (Karachi, Sindh and 1 other locations)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedJune 2026
Study endsDecember 2026
Registry record updatedSeptember 19, 2025
Trial IDNCT06707012 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 45 with a BMI over 25 and a recent diagnosis of depression.

Probably not a fit

Patients with existing diabetes or other significant psychiatric disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of metformin as an additional treatment for improving depressive symptoms in newly diagnosed obese patients already receiving standard antidepressant therapy. Participants will be randomly assigned to either a metformin group or a placebo group, with the primary outcome being the reduction in Hamilton Depression Rating Scale (HAM-D) scores. Secondary outcomes will assess oxidative stress markers through enzymatic activity measurements. The study aims to determine if metformin can significantly enhance the treatment of depression in this specific patient population.

Why it matters

Potential benefit: If successful, this approach could lead to improved treatment outcomes for obese patients suffering from depression.

How similar studies have gone: While the combination of metformin and antidepressants is a novel approach, similar studies have shown promise in addressing metabolic issues in depressed patients.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* • Age \>18 to \<45 years

  * Gender: Both genders (Male and Female)
  * BMI \>25
  * Diagnosis: Newly diagnose cases of depression (mild to severe)
  * HBA1C: Less than 5.7% (non-diabetic range)

Exclusion Criteria:

* Existing diabetes

  * Acute illnesses like acute kidney injury, recent history of myocardial infarction, acute liver injury
  * Intellectual disabilities or inability to understand due to any reason
  * Presence of Psychiatric disorders other than depression
  * Chronic kidney disease (eGFR \< 45 mL/min/1.73 m²).
  * Use of any psychotropic medication within the past 6 months.

Where it's running

  • Fazaia Rurh Pfau Medical College
    Karachi, Sindh, Pakistan
    Recruiting
  • Fazaia Ruth Pfau Medical College
    Karachi, Sindh, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.